FGH10019

1046045-61-7

C18H19N3O2S2

DMSO : >= 38 mg/mL (101.74 mM)

Others

FGH10019 is a novel sterol regulatory element-binding protein (SREBP) inhibitor with IC₅₀ of 1 uM. IC50 & Target: IC50: 1 uM (SREBP) In Vitro: Treatment of the CHO-K1 cells with analog FGH10019 decreases the percentage of the mature form of SREBP-2 (68 kDa) at lower concentrations than treatment with fatostatin. Densitometric analysis of the gels indicates that the IC₅₀ of analog FGH10019 is approximately 1 uM, which is 5-10 times lower than the IC₅₀ of fatostatin (appr 10 uM)^[1]. In Vivo: FGH10019-treated chow is fed at a dose rate calculated to provide about 0.7 mg analog FGH10019 per day, at about 23 mg/kg body weight, to 5-wk-old male ob/ob mice weighing an average of appr 30 g. After 8 wk on the analog 24-treated chow, the mice gain 8-9 % less weight than control mice^[1].